tradingkey.logo

Vor Biopharma Inc

VOR

2.170USD

0.000
Close 08/22, 16:00ETQuotes delayed by 15 min
272.65MMarket Cap
LossP/E TTM

Vor Biopharma Inc

2.170

0.000
More Details of Vor Biopharma Inc Company
Vor Biopharma Inc. is a clinical-stage cell and genome engineering therapy company. The Company is engaged in combining a novel patient engineering approach with targeted therapies to provide solutions for patients suffering from hematological malignancies. Its proprietary platform leverages expertise in hematopoietic stem cell (HSC) biology, genome engineering and targeted therapy development to genetically modify HSCs to remove surface targets expressed by cancer cells. The Company’s lead engineered hematopoietic stem cells (eHSC) product candidate include tremtelectogene empogeditemcel (trem-cel), for the treatment for acute myeloid leukemia (AML) and other blood cancers. It is designed to replace the standard of care in transplant settings for patients suffering from acute myeloid leukemia (AML) and other blood cancers. Its VBP101 is a Phase I/II a multicenter, open-label, first-in-human study of trem-cel in patients with AML.
Company Info
Ticker SymbolVOR
Company nameVor Biopharma Inc
IPO dateFeb 05, 2021
CEODr. Jean-Paul Kress, M.D.
Number of employees159
Security typeOrdinary Share
Fiscal year-endFeb 05
Address100 Cambridgepark Drive
CityCAMBRIDGE
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code02140
Phone16176556580
Websitehttps://www.vorbio.com/
Ticker SymbolVOR
IPO dateFeb 05, 2021
CEODr. Jean-Paul Kress, M.D.
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Sandesh (Sandy) Mahatme
Mr. Sandesh (Sandy) Mahatme
Chief Financial Officer, Chief Business Officer
Chief Financial Officer, Chief Business Officer
13.88M
--
Dr. Qing Zuraw
Dr. Qing Zuraw
Chief Development Officer
Chief Development Officer
937.08K
--
Mr. Erez Kalir
Mr. Erez Kalir
Independent Director
Independent Director
--
--
Mr. David Charles Lubner, CPA
Mr. David Charles Lubner, CPA
Independent Director
Independent Director
--
--
Dr. Fouad Namouni, M.D.
Dr. Fouad Namouni, M.D.
Independent Director
Independent Director
--
--
Dr. Joshua B. (Josh) Resnick, M.D.
Dr. Joshua B. (Josh) Resnick, M.D.
Independent Director
Independent Director
--
--
Ms. Daniella Beckman, CPA
Ms. Daniella Beckman, CPA
Independent Director
Independent Director
--
--
Dr. Jean-Paul Kress, M.D.
Dr. Jean-Paul Kress, M.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
--
--
Mr. Dallan Murray
Mr. Dallan Murray
Chief Commercial Officer
Chief Commercial Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Sandesh (Sandy) Mahatme
Mr. Sandesh (Sandy) Mahatme
Chief Financial Officer, Chief Business Officer
Chief Financial Officer, Chief Business Officer
13.88M
--
Dr. Qing Zuraw
Dr. Qing Zuraw
Chief Development Officer
Chief Development Officer
937.08K
--
Mr. Erez Kalir
Mr. Erez Kalir
Independent Director
Independent Director
--
--
Mr. David Charles Lubner, CPA
Mr. David Charles Lubner, CPA
Independent Director
Independent Director
--
--
Dr. Fouad Namouni, M.D.
Dr. Fouad Namouni, M.D.
Independent Director
Independent Director
--
--
Dr. Joshua B. (Josh) Resnick, M.D.
Dr. Joshua B. (Josh) Resnick, M.D.
Independent Director
Independent Director
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Tue, Aug 19
Updated: Tue, Aug 19
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
RA Capital Management, LP
31.30%
Reprogrammed Interchange LLC
30.77%
Mahatme (Sandesh)
10.96%
5AM Ventures
3.49%
Fidelity Management & Research Company LLC
1.59%
Other
21.90%
Shareholders
Shareholders
Proportion
RA Capital Management, LP
31.30%
Reprogrammed Interchange LLC
30.77%
Mahatme (Sandesh)
10.96%
5AM Ventures
3.49%
Fidelity Management & Research Company LLC
1.59%
Other
21.90%
Shareholder Types
Shareholders
Proportion
Venture Capital
35.67%
Corporation
30.77%
Individual Investor
12.08%
Investment Advisor
5.49%
Hedge Fund
0.98%
Research Firm
0.71%
Investment Advisor/Hedge Fund
0.67%
Bank and Trust
0.14%
Other
13.51%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
165
100.29M
80.27%
+23.22M
2025Q1
174
100.82M
80.73%
+21.38M
2024Q4
172
101.57M
81.78%
+39.14M
2024Q3
175
49.60M
72.03%
-12.93M
2024Q2
174
56.25M
82.04%
-8.25M
2024Q1
168
60.63M
88.57%
-4.75M
2023Q4
163
60.90M
89.54%
-3.77M
2023Q3
164
61.10M
90.20%
-4.10M
2023Q2
166
61.68M
92.10%
-1.24M
2023Q1
168
61.85M
93.27%
-1.28M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
RA Capital Management, LP
39.65M
31.73%
--
--
Jun 25, 2025
Reprogrammed Interchange LLC
38.97M
31.19%
+38.97M
--
Dec 30, 2024
5AM Ventures
6.36M
5.09%
--
--
Mar 31, 2025
Fidelity Management & Research Company LLC
6.34M
5.07%
+5.39K
+0.09%
Mar 31, 2025
The Vanguard Group, Inc.
1.94M
1.55%
-2.60K
-0.13%
Mar 31, 2025
Johnson & Johnson Innovation-JJDC, Inc.
1.07M
0.86%
--
--
Mar 31, 2025
Jane Street Capital, L.L.C.
194.76K
0.16%
+194.76K
--
Mar 31, 2025
View more
Related ETFs
Updated: Wed, Aug 6
Updated: Wed, Aug 6
Name
Proportion
ProShares UltraPro Russell2000
0%
ProShares Hedge Replication ETF
0%
iShares Russell 2000 ETF
0%
Global X Russell 2000 ETF
0%
iShares Micro-Cap ETF
0%
iShares Russell 2000 Value ETF
0%
Global X Russell 2000 Covered Call ETF
0%
Proshares Ultra Russell 2000
0%
Dimensional US Core Equity 1 ETF
0%
ProShares UltraPro Russell2000
Proportion0%
ProShares Hedge Replication ETF
Proportion0%
iShares Russell 2000 ETF
Proportion0%
Global X Russell 2000 ETF
Proportion0%
iShares Micro-Cap ETF
Proportion0%
iShares Russell 2000 Value ETF
Proportion0%
Global X Russell 2000 Covered Call ETF
Proportion0%
Proshares Ultra Russell 2000
Proportion0%
Dimensional US Core Equity 1 ETF
Proportion0%
Dividend
A total of 0.00 USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
KeyAI